IP Verse

Tablets Comprising Glp-1 Agonist And Enteric Coating - EP3250191

The patent EP3250191 was granted to Novo Nordisk on Jan 17, 2024. The application was originally filed on Jan 28, 2016 under application number EP16701684A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3250191

NOVO NORDISK
Application Number
EP16701684A
Filing Date
Jan 28, 2016
Status
Granted And Under Opposition
Dec 15, 2023
Grant Date
Jan 17, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

HEXALOct 17, 2024MAIWALDADMISSIBLE

Patent Citations (9) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
EXAMINATIONWO2011084618
INTERNATIONAL-SEARCH-REPORTUS2011142889
INTERNATIONAL-SEARCH-REPORTWO2009118722
INTERNATIONAL-SEARCH-REPORTWO2014060472
INTERNATIONAL-SEARCH-REPORTWO2014191545
OPPOSITIONWO2006097537
OPPOSITIONWO2010020978
OPPOSITIONWO2011094531
OPPOSITIONWO2014177683

Non-Patent Literature (NPL) Citations (8) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Anonymous, "A Comparison of Delayed Release Film Coating Systems for Pharmaceutical Dosage Forms", Acryl-EZE - Colorcon, (20110401), pages 1 - 5, XP093232478-
OPPOSITION- Anonymous, "Eudragit - Acrylic polymers for solid oral dosage forms", Evonk, (20120801), vol. V 2.3, pages 1 - 16, XP093232470-
OPPOSITION- Anonymous , "Polymethacrylates", Anonymous , Raymond C Row , Paul J Sheskey , Marian E Quinn, Handbook of Pharmaceutical Excipients sixth Edition, Pharmaceutical Press, (20090101), pages 525 - 533, XP093232497-
OPPOSITION- Anonymous, "Product Information ", Acryl-EZE - Colorcon, (20110101), pages 1 - 5, XP093232488-
OPPOSITION- Bai Jane P.F, Jian-Hwa Guo , Mahesh V. Chaubal, "Chapter 12 Use of Nonactive Pharmaceutical Excipients in Oral Drug Formulations: Biopharmaceutical Classification System Considerations", Bai Jane P.F, Jian-Hwa Guo , Mahesh V. Chaubal, Ashok Katdare; Mahesh V. Chaubal, Excipient development for pharmaceutical, biotechnology, and drug delivery systems, New York, Informa Healthcare , (20060101), pages 181 - 195, ISBN 978-0-8493-2706-3, XP093232462-
OPPOSITION- C Beglinger, B PoIler, E Arbit, C Ganzoni, S Gass, I Gomez-Orellana, J Drewe, "Pharmacokinetics and Pharmacodynamic Effects of Oral GLP-1 and PYY3-36: A Proof-of-concept Study in Healthy Subjects", Clinical Pharmacology and Therapeutics, US , (20081001), vol. 84, no. 4, doi:10.1038/clpt.2008.35, ISSN 0009-9236, pages 468 - 474, XP008149454
OPPOSITION- Steinert Robert E , Poller Birk , Castelli M Cristina , Drewe Juergen , Beglinger Christoph, "Orally Administered Glucagon-Like Peptide-1 Affects Glucose Homeostasis Following an Oral Glucose Tolerance Test in Healthy Male Subjects", Clinical Pharmacology and Therapeutics, US , (20091201), vol. 86, no. 6, doi:10.1038/clpt.2009.159, ISSN 0009-9236, pages 644 - 650, XP002635568
OPPOSITION- Robert E Steinert, Birk Poller, M Cristina Castelli, Juergen Drewe, Christoph Beglinge, "Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects.", American Journal of Clinical Nutrition, (20101001), vol. 92, no. 4, doi:10.3945/ajcn.2010.29663, ISSN 0002-9165, pages 810 - 817, XP002677085

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents